Navigation Links
ThromboGenics Announces Business Update and 2008 Full Year Results
Date:3/12/2009

s compares to EUR 40.1 million in cash and EUR 6.7 million in short term investments at December 31, 2007. This level of cash resources is expected to allow ThromboGenics to drive forward its operational plans for the next two years.

Patrik De Haes, CEO of ThromboGenics, commenting on today's announcement, said: "ThromboGenics had a very successful 2008, making excellent progress with its development pipeline and reporting a pre-tax profit for the period. The recent start of our Phase III program with microplasmin in patients with back of the eye disease is a major milestone for the Company. Our decision to initiate this pivotal clinical program was driven by the excellent clinical Phase II data that we have generated, combined with our strong financial position. This is the result of the EUR30m upfront payment we received as part of our major strategic licensing deal for TB-403 with Roche, signed in June 2008. We are also making good progress with TB-402, a novel long acting anti-coagulant which we believe has advantages over currently marketed products. As ThromboGenics continues to transform itself into a late-stage development company, I am confident that we have all the tools needed to ensure our corporate success."

For the full report of these results please go to http://www.thrombogenics.com

About ThromboGenics

ThromboGenics is a biotechnology company focused on the discovery and development of biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company's lead product Microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications and as a potential therapy for stroke. ThromboGenics is also developing novel antibody
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
2. ThromboGenics N.V.: Business Update
3. ThromboGenics Announces Half Year Results 2008
4. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
5. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
6. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
7. ThromboGenics N.V. - Business Update
8. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
9. ThromboGenics Announces 2007 Full Year Results
10. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
11. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... WORMS, GERMANY – May 26, ... GRA) announces that its manufacturing facility in Worms, ... from EXCiPACT™, an independent organization that certifies manufacturers, ... , All three Grace facilities that produce its ... gels have now received GMP certification, following the ...
(Date:5/26/2015)... May 26, 2015   Intrexon Corporation (NYSE: ... Gregory Frost , Ph.D., Senior Vice President and Head ... Global Healthcare Conference on Wednesday, June 3 rd , at ... New York City . About Intrexon ... Powering the Bioindustrial Revolution with Better DNA ™ to ...
(Date:5/26/2015)... , May 26, 2015   PDI , ... today announced that Oakwood Healthcare in ... the winning entry in Delivering the ... who display excellence in building collaborative relationships between ... in healthcare facilities.  Oakwood Healthcare,s ...
(Date:5/26/2015)... , May 26, 2015 Mr. Kevin ... family, thanks President Barack Obama and President ... the time of loss of Dr. Rongxiang Xu , ... and a leader ahead of his time, Dr. Xu,s commitment ... community leave a legacy that will not be forgotten. As ...
Breaking Biology Technology:CORRECTION: Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2Intrexon to Present at the Jefferies 2015 Global Healthcare Conference 2PDI Announces Winner in Delivering the Difference Contest 2PDI Announces Winner in Delivering the Difference Contest 3Dr. Rongxiang Xu, Beyond A Legend 2
... Board of Directors of the Pittsburgh Life Sciences Greenhouse ... formation and business growth services to the region,s life ... of Peter M. DeComo as the new Chairman of ... will replace Dr. D. Lansing Taylor who is stepping ...
... hair-like blood vessels in the back of our eyes, researchers ... those that bring blood to the heart respond to air ... otherwise healthy people exposed to high levels of air pollution ... of heart disease. Previous studies linked pollution to heart ...
... In 2008, experiments at The Fu Foundation School of ... graphene, a single layer of graphite only one atom ... raised a question for Chris Marianetti, Assistant Professor in ... how and why does graphene break? ...
Cached Biology Technology:The Pittsburgh Life Sciences Greenhouse Announces New Chairman of the Board 2Photos of tiny blood vessels in the eye link air pollution to heart disease 2Columbia engineering team discovers graphene's weakness 2
(Date:5/11/2015)... Curemark LLC, a privately held drug research ... Phase III double blind, randomized, placebo-controlled clinical trial to ... all children ages 3-8 with Autism. Previously, Curemark announced ... blinded clinical trial for CM-AT in children ages 3-8 ... enzyme chymotrypsin. This new trial will help determine whether ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, reminds investors and media that  Mr. ...  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of nine ... Global Fraud: Where is the Trust in Cyberspace? ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... The founder of a public database that helps doctors ... decisions is the 2009 recipient of the March of ... field of genetic sciences. Roberta "Bonnie" Pagon, MD, ... of Medicine in Seattle, developed the Web site genetests.org ...
... have observed the initiation of a mass gathering and subsequent ... case, fish. The work, conducted using a novel imaging ... that vast oceanic fish shoals inhabit," the team writes in ... also confirms theories about the behavior of large groups of ...
... unveiled the evolutionary origin of the different chromosomal ... comprehensive comparison of the Agrobacterium sequence information with ... general model for how second chromosomes are formed ... Rhizobiaceae family, which also includes the benign, nitrogen-fixing ...
Cached Biology News:Roberta A. Pagon receives lifetime award in genetics from March of Dimes 2Team IDs genesis of mass migrations 2Team IDs genesis of mass migrations 3Evolutionary origin of bacterial chromosomes revealed 2
... Ready-to-use liquid controls for monitoring Aldolase ... & abnormal) with targeted manufacturing values ... 20 ± 3 IU/L. 30-day ... at 2-8 C. Level 1: 3 ...
Request Info...
One-step, microplate or cuvet, colorimetric, linear detection range 0.2 mg/dL to 20 mg/dL. Procedure: 20 min....
Recombinant Mouse Noggin...
Biology Products: